Association of progression-free survival with overall survival (OS) in patients (pts) with neuroendocrine tumor (NET) treated with somatostatin analogs.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Dana-Farber Cancer Institute, Harvard University, Ipsen (France)
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2601828615
